The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
JAK2 phosphorylates histone H3Y41 and excludes HP1α from chromatin
Open accessAbstract
Activation of Janus kinase 2 (JAK2) by chromosomal translocations or point mutations is a frequent event in haematological malignancies. JAK2 is a non-receptor tyrosine kinase that regulates several cellular processes by inducing cytoplasmic signalling cascades. Here we show that human JAK2 is present in the nucleus of haematopoietic cells and directly phosphorylates Tyr 41 (Y41) on histone H3. Heterochromatin protein 1α (HP1α), but not HP1β, specifically binds to this region of H3 through its chromo-shadow domain. Phosphorylation of H3Y41 by JAK2 prevents this binding. Inhibition of JAK2 activity in human leukaemic cells decreases both the expression of the haematopoietic oncogene lmo2 and the phosphorylation of H3Y41 at its promoter, while simultaneously increasing the binding of HP1α at the same site. These results identify a previously unrecognized nuclear role for JAK2 in the phosphorylation of H3Y41 and reveal a direct mechanistic link between two genes, jak2 and lmo2, involved in normal haematopoiesis and leukaemia.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Chromatin modifications and their function
Kouzarides, T. (2007) · Cell · doi:10.1016/j.cell.2007.02.005 · Cited by 10,883
Self-citationAcquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
Baxter, E. J., Scott, L. M., Campbell, P. J., East, C., Fourouclas, N., Swanton, S., Vassiliou, G. S., Bench, A. J., Boyd, E. M., Curtin, N., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71142-9 · Cited by 3,548
Self-citationA unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
James, C., Ugo, V., Le Couédic, J.-P., Staerk, J., Delhommeau, F., Lacout, C., Garçon, L., Raslova, H., Berger, R., Bennaceur-Griscelli, A., et al. (2005) · Nature · doi:10.1038/nature03546 · Cited by 3,544
A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
Kralovics, R., Passamonti, F., Buser, A. S., Teo, S.-S., Tiedt, R., Passweg, J. R., Tichelli, A., Cazzola, M., & Skoda, R. C. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051113 · Cited by 3,470
Levine, R. L., Wadleigh, M., Cools, J., Ebert, B. L., Wernig, G., Huntly, B. J. P., Boggon, T. J., Wlodarska, I., Clark, J. J., Moore, S., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.03.023 · Cited by 2,993
Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain
Bannister, A. J., Zegerman, P., Partridge, J. F., Miska, E. A., Thomas, J. O., Allshire, R. C., & Kouzarides, T. (2001) · Nature · doi:10.1038/35065138 · Cited by 2,903
Self-citationMethylation of histone H3 lysine 9 creates a binding site for HP1 proteins
Lachner, M., O'Carroll, D., Rea, S., Mechtler, K., & Jenuwein, T. (2001) · Nature · doi:10.1038/35065132 · Cited by 2,868
The CBP co-activator is a histone acetyltransferase
Bannister, A. J., & Kouzarides, T. (1996) · Nature · doi:10.1038/384641a0 · Cited by 1,805
Self-citationOsborn, L., Kunkel, S., & Nabel, G. J. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.7.2336 · Cited by 1,621
JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis
Scott, L. M., Tong, W., Levine, R. L., Scott, M. A., Beer, P. A., Stratton, M. R., Futreal, P. A., Erber, W. N., McMullin, M. F., Harrison, C. N., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa065202 · Cited by 1,276
Self-citationO'Shea, J. J., Gadina, M., & Schreiber, R. D. (2002) · Cell · doi:10.1016/s0092-8674(02)00701-8 · Cited by 1,119
The Myeloproliferative Disorders
Campbell, P. J., & Green, A. R. (2006) · New England Journal of Medicine · doi:10.1056/nejmra063728 · Cited by 915
Self-citationJak2 Deficiency Defines an EssentialDevelopmental Checkpoint in DefinitiveHematopoiesis
Neubauer, H., Cumano, A., Müller, M., Wu, H., Huffstadt, U., & Pfeffer, K. (1998) · Cell · doi:10.1016/s0092-8674(00)81168-x · Cited by 914
Rb targets histone H3 methylation and HP1 to promoters
Nielsen, S. J., Schneider, R., Bauer, U.-M., Bannister, A. J., Morrison, A., O'Carroll, D., Firestein, R., Cleary, M., Jenuwein, T., Herrera, R. E., et al. (2001) · Nature · doi:10.1038/35087620 · Cited by 904
Self-citationReconstitution of Nucleosome Core Particles from Recombinant Histones and DNA
Dyer, P. N., Edayathumangalam, R. S., White, C. L., Bao, Y., Chakravarthy, S., Muthurajan, U. M., & Luger, K. (2003) · Methods in Enzymology · doi:10.1016/s0076-6879(03)75002-2 · Cited by 864
A TEL-JAK2 Fusion Protein with Constitutive Kinase Activity in Human Leukemia
Lacronique, V., Boureux, A., Della Valle, V., Poirel, H., Quang, C. T., Mauchauffé, M., Berthou, C., Lessard, M., Berger, R., Ghysdael, J., et al. (1997) · Science · doi:10.1126/science.278.5341.1309 · Cited by 791
Fetal Anemia and Apoptosis of Red Cell Progenitors in Stat5a−/−5b−/− Mice
Socolovsky, M., Fallon, A. E. J., Wang, S., Brugnara, C., & Lodish, H. F. (1999) · Cell · doi:10.1016/s0092-8674(00)81013-2 · Cited by 696
Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders
Levine, R. L., Pardanani, A., Tefferi, A., & Gilliland, D. G. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2210 · Cited by 588
JAK mutations in high-risk childhood acute lymphoblastic leukemia
Mullighan, C. G., Zhang, J., Harvey, R. C., Collins-Underwood, J. R., Schulman, B. A., Phillips, L. A., Tasian, S. K., Loh, M. L., Su, X., Liu, W., et al. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0811761106 · Cited by 562
Watling, D., Guschin, D., Müller, M., Silvennoinen, O., Witthuhn, B. A., Quelle, F. W., Rogers, N. C., Schindler, C., Stark, G. R., Ihle, J. N., et al. (1993) · Nature · doi:10.1038/366166a0 · Cited by 533
Mutations of JAK2 in acute lymphoblastic leukaemias associated with Down's syndrome
Bercovich, D., Ganmore, I., Scott, L. M., Wainreb, G., Birger, Y., Elimelech, A., Shochat, C., Cazzaniga, G., Biondi, A., Basso, G., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61341-0 · Cited by 337
Self-citationThe T cell leukemia LIM protein Lmo2 is necessary for adult mouse hematopoiesis
Yamada, Y., Warren, A. J., Dobson, C., Forster, A., Pannell, R., & Rabbitts, T. H. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3890 · Cited by 302
McCormack, M. P., & Rabbitts, T. H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra032207 · Cited by 278
Pardanani, A., Hood, J., Lasho, T., Levine, R. L., Martin, M. B., Noronha, G., Finke, C., Mak, C. C., Mesa, R., Zhu, H., et al. (2007) · Leukemia · doi:10.1038/sj.leu.2404750 · Cited by 272
Slupianek, A., Hoser, G., Majsterek, I., Bronisz, A., Malecki, M., Blasiak, J., Fishel, R., & Skorski, T. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.12.4189-4201.2002 · Cited by 207
Heterochromatin links to centromeric protection by recruiting shugoshin
Yamagishi, Y., Sakuno, T., Shimura, M., & Watanabe, Y. (2008) · Nature · doi:10.1038/nature07217 · Cited by 187
Krude, T. (1999) · Experimental Cell Research · doi:10.1006/excr.1998.4342 · Cited by 183
JAK signaling globally counteracts heterochromatic gene silencing
Shi, S., Calhoun, H. C., Xia, F., Li, J., Le, L., & Li, W. X. (2006) · Nature Genetics · doi:10.1038/ng1860 · Cited by 177
Plo, I., Nakatake, M., Malivert, L., de Villartay, J.-P., Giraudier, S., Villeval, J.-L., Wiesmuller, L., & Vainchenker, W. (2008) · Blood · doi:10.1182/blood-2008-01-134114 · Cited by 177
JAK2 V617F tyrosine kinase mutation in cell lines derived from myeloproliferative disorders
Quentmeier, H., MacLeod, R. A. F., Zaborski, M., & Drexler, H. G. (2006) · Leukemia · doi:10.1038/sj.leu.2404081 · Cited by 157
Involvement of Jak2 tyrosine phosphorylation in Bcr–Abl transformation
Xie, S., Wang, Y., Liu, J., Sun, T., Wilson, M. B., Smithgall, T. E., & Arlinghaus, R. B. (2001) · Oncogene · doi:10.1038/sj.onc.1204834 · Cited by 146
Histone Tails and the H3 αN Helix Regulate Nucleosome Mobility and Stability
Ferreira, H. C., Somers, J., Webster, R., Flaus, A., & Owen‐Hughes, T. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.02229-06 · Cited by 136
Activated Jak2 with the V617F Point Mutation Promotes G1/S Phase Transition
Walz, C., Crowley, B. J., Hudon, H. E., Gramlich, J. L., Neuberg, D. S., Podar, K., Griffin, J. D., & Sattler, M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m600064200 · Cited by 117
Garçon, L., Rivat, C., James, C., Lacout, C., Camara‐Clayette, V., Ugo, V., Lécluse, Y., Griscelli, A. B., & Vainchenker, W. (2006) · Blood · doi:10.1182/blood-2005-10-009514 · Cited by 107
Inhibition of the Bcl-x L Deamidation Pathway in Myeloproliferative Disorders
Zhao, R., Follows, G., Beer, P. A., Scott, L. M., Huntly, B. J. P., Green, A. R., & Alexander, D. R. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804953 · Cited by 101
Self-citationThe role of jak2a in zebrafish hematopoiesis
Ma, A. C. H., Ward, A. C., Liang, R. H. S., & Leung, A. Y. H. (2007) · Blood · doi:10.1182/blood-2007-03-078287 · Cited by 66
Krude, T. (2000) · Journal of Biological Chemistry · doi:10.1074/jbc.275.18.13699 · Cited by 60
HP1α guides neuronal fate by timing E2F‐targeted genes silencing during terminal differentiation
Panteleeva, I., Boutillier, S., Sée, V., Spiller, D. G., Rouaux, C., Almouzni, G., Bailly, D., Maison, C., Lai, H. C., Loeffler, J., et al. (2007) · The EMBO Journal · doi:10.1038/sj.emboj.7601789 · Cited by 56
Wood, A. D., Chen, E., Donaldson, I. J., Hattangadi, S. M., Burke, K. A., Dawson, M. A., Miranda‐Saavedra, D., Lodish, H. F., Green, A. R., & Göttgens, B. (2009) · Blood · doi:10.1182/blood-2009-02-206573 · Cited by 51
Self-citationChromatin Structure Regulates Gene Conversion
Cummings, W. J., Yabuki, M., Ordinario, E., Bednarski, D. W., Quay, S., & Maizels, N. (2007) · PLoS Biology · doi:10.1371/journal.pbio.0050246 · Cited by 46
Schuringa, J. J., & Schepers, H. (2009) · Methods in molecular biology · doi:10.1007/978-1-59745-418-6_14 · Cited by 37
TFBScluster: a resource for the characterization of transcriptional regulatory networks
Donaldson, I. J., Chapman, M., & Göttgens, B. (2005) · Computer applications in the biosciences · doi:10.1093/bioinformatics/bti461 · Cited by 29
Self-citation
Cited by
Regulation of chromatin by histone modifications
Bannister, A. J., & Kouzarides, T. (2011) · Cell Research · doi:10.1038/cr.2011.22 · Cited by 6,012
Self-citationCancer epigenetics: from mechanism to therapy
Dawson, M. A., & Kouzarides, T. (2012) · Cell · doi:10.1016/j.cell.2012.06.013 · Cited by 3,203
Self-citationEpigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Revisiting STAT3 signalling in cancer: new and unexpected biological functions
Yu, H., Lee, H., Herrmann, A., Buettner, R., & Jove, R. (2014) · Nature Reviews Cancer · doi:10.1038/nrc3818 · Cited by 2,137
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Dawson, M. A., Prinjha, R. K., Dittmann, A., Giotopoulos, G., Bantscheff, M., Chan, W.-I., Robson, S. C., Chung, C.-W., Hopf, C., Savitski, M. M., et al. (2011) · Nature · doi:10.1038/nature10509 · Cited by 1,503
Self-citation
Metadata
- Authors
- Dawson, M. A., Bannister, A. J., Göttgens, B., Foster, S. D., Bartke, T., Green, A. R., & Kouzarides, T.
- Venue
- Nature
- Published
- 2009-09-27
- Volume
- 461
- Issue
- 7265
- Pages
- 819-822
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2051181798
- Cited by
- 622
- References
- 42
- FWCI
- 23.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.